Dabrafenib (GSK2118436)

For research use only. Not for use in humans.

目录号：S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1481.39	现货
5mg	RMB 733.64	现货
10mg	RMB 1056.75	现货
20mg	RMB 1394.46	现货
50mg	RMB 2235.84	现货
100mg	RMB 3261.37	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dabrafenib (GSK2118436)发表文献135篇：

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )
Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )
Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )
ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )
Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )
Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

靶点

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

体外研究

Dabrafenib对Raf激酶具有选择性，对B-Raf的活性比其它测试过的91%的激酶高400倍。 Dabrafenib抑制B-Raf^V600E激酶，导致ERK磷酸化降低和抑制细胞的增值，在特异性编码突变的B-Raf^V600E的癌细胞中细胞停滞在G1期。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	M1;iUmtqdmG\|ZTDBd5NigQ>?				NYC3UZhJUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqeyC2YXfn[YQhSi2UYX[gWlYxOEVibYX0ZY51KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiY3:t[ZhxemW\|c3nu[{BETEN\|NzDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCkaX;0bY56dGG2ZXStUWVMKHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIJ6KEGucHjhV4Nz\WWwIHHzd4F6KHerdHigTWM2OCCxZjCwMlAxODdizszN	M2HmTlI1QTByNkez
SK-MEL-28	MmPGT4lv[XOnIFHzd4F6		Mn;sNUBp		NWPnSWRmUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSgbY4hcHWvYX6gV2suVUWOLUK4JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEWUSzDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB2IN88US=>	MX6yOFkxODZ5Mx?=
HepG2	M4HrZWtqdmG\|ZTDBd5NigQ>?				MVjJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByNDFOwG0>	M1GyOVI1QTByNkez
COLO205	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9{MEWgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwO{DPxE1?	NIr4TngzPDlyME[3Ny=>
HepG2	M{PYfWZ2dmO2aX;uJGF{e2G7		M4PrflQ2KG2rbh?=	MUDEUXNQ	MVPJcohq[mm2aX;uJI9nKEGua{WgbY4hXEeILXLleIEue3SrbYXsZZRm\CCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBUdWGmMjDwbI9{eGixconsZZRqd25idILlZZRm\CCob4KgOFUhdWmwczDwdolweiC2bzDUS2Yu[mW2YTDzeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjC2NEBucW6\|IHL5JI9lgXO\|ZYmgZoxwfCC\|Y3HucoVzKGGwYXz5d4l{KHerdHigTWM2OCCxZjCzMlch\|ryP	MkHHNlQ6ODB4N{O=
HFF	M2S5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWixNEDPxE1?	MUS3NkBp	MlzaSG1UVw>?	NHjhZolKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiaIXtZY4hUE[IIHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGViQj3SZYYhf2m2aDDJR\|UxKG:oIEOg{txO	M2C0TVI{QDR2MEO4
SK-MEL-28	M3fvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3G3flExKM7:TR?=	NGHUeHc4OiCq	MWPEUXNQ	M{HrOGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCVSz3NSWwuOjhiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB2MzFOwG0>	M3vlfVI{QDR2MEO4
A375P-F11	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3P6dFExKM7:TR?=	NYfZeVlsPzJiaB?=	MYfEUXNQ	M3zzNWlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCDM{e1VE1HOTFiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB5MTFOwG0>	MUiyN\|g1PDB\|OB?=
MALME-3M	M{K2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWmxNEDPxE1?	NVLIbW51PzJiaB?=	MoXOSG1UVw>?	MU\JR\|UxRTFibl2=	NVjUfHFCOjN6NESwN\|g>
UACC-62	M2[1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4K5U\|ExKM7:TR?=	NFTxWWI4OiCq	NW[3TVlITE2VTx?=	NE[we5BKSzVyPUGgcm0>	NELh[mQzOzh2NECzPC=>
C32TG	M1H5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInyOoQyOCEQvF2=	NVniTZpzPzJiaB?=	MnnnSG1UVw>?	MV;JR\|UxRTFibl2=	Mmj5NlM5PDRyM{i=
SK-MEL-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXH3c3BROTBizszN	NES1XYs4OiCq	NEnnVXlFVVOR	MlTZTWM2OD1{IH7N	MkXHNlM5PDRyM{i=
M14	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfCNVAh\|ryP	NVzzb4l6PzJiaB?=	M1K1R2ROW09?	MWPJR\|UxRTJibl2=	MmLjNlM5PDRyM{i=
SK-MEL-28	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TPc\|ExKM7:TR?=	M33kU\|czKGh?	MoTNSG1UVw>?	M2m0b2lEPTB;MzDuUS=>	MYGyN\|g1PDB\|OB?=
A375	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrMNVAh\|ryP	MYm3NkBp	NVPsbY9CTE2VTx?=	NHvuTFJKSzVyPUSgcm0>	MXeyN\|g1PDB\|OB?=
DU-4475	NEfDNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2q5VlExKM7:TR?=	NIK3WGc4OiCq	Ml7MSG1UVw>?	M{fXUGlEPTB;NTDuUS=>	MUiyN\|g1PDB\|OB?=
UACC-257	NWTadXN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\uflExKM7:TR?=	NGnsUoY4OiCq	NITvbHNFVVOR	MVvJR\|UxRTZibl2=	MYKyN\|g1PDB\|OB?=
Colo 205	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrnNVAh\|ryP	NI\sToM4OiCq	MmLsSG1UVw>?	MlLVTWM2OD15IH7N	MVSyN\|g1PDB\|OB?=
SK-MEL-3	NFHPNHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moq2NVAh\|ryP	NVvXVWJqPzJiaB?=	MXrEUXNQ	NVn0dGZkUUN3ME23JI5O	MX6yN\|g1PDB\|OB?=
SH-4	NUT6eY1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTaenBNOTBizszN	NHfE[XQ4OiCq	MV;EUXNQ	MXLJR\|UxRThibl2=	NED5eXMzOzh2NECzPC=>
A101D	NU\hVXdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPKNVAh\|ryP	M2LHV\|czKGh?	Mlf6SG1UVw>?	NVzFb2xbUUN3ME25JI5O	MX6yN\|g1PDB\|OB?=
ES-2	NYfGcnFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\INlExKM7:TR?=	M33TfVczKGh?	MWDEUXNQ	MkLrTWM2OD13MzDuUS=>	NVXwSZlrOjN6NESwN\|g>
HT-29	M3nFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmflNVAh\|ryP	MmLmO\|IhcA>?	M3;lUGROW09?	MV3JR\|UxRTZ4IH7N	MWGyN\|g1PDB\|OB?=
SW1417	NWHWVFd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfKTZEyOCEQvF2=	Mn7CO\|IhcA>?	NEP5bnFFVVOR	M2rnS2lEPTB;MUW4JI5O	MoHjNlM5PDRyM{i=
SW872	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jLelExKM7:TR?=	M2HXUlczKGh?	M{PlbmROW09?	MVnJR\|UxRTN5NzDuUS=>	MUKyN\|g1PDB\|OB?=
RKO	NGjEN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\J[5IyOCEQvF2=	M4H4d\|czKGh?	M2XDNWROW09?	MUDJR\|UxRTJwNUKyJO69VQ>?	MVOyN\|g1PDB\|OB?=
A673	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWC5d5JOOTBizszN	Mlv6O\|IhcA>?	Mkf5SG1UVw>?	NYm2W2YxUUN3ME2xNEDPxE1?	MlfDNlM5PDRyM{i=
GCT	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYqxNEDPxE1?	MYK3NkBp	NWK3cpp2TE2VTx?=	NF:2cpJKSzVyPUGwJO69VQ>?	Mm\ONlM5PDRyM{i=
WM-115	M2XrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\FO5MyOCEQvF2=	NXW2OmpLPzJiaB?=	NYKyNogzTE2VTx?=	NHH1UnBKSzVyPUWgcm0>	MmHaNlM5PDRyM{i=
YUMAC	NXfjfGhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rlZ\|ExKM7:TR?=	NITB[mw4OiCq	NHX1U\|lFVVOR	M4\xdWlEPTB;NTDuUS=>	MnzQNlM5PDRyM{i=
OV-90	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYqxNEDPxE1?	NX\y[JpRPzJiaB?=	MnTTSG1UVw>?	NHO0eVlKSzVyPUK5JI5O	NW\uVnd6OjN6NESwN\|g>
NCI-H508	NF;Pc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\6NVAh\|ryP	M2fyPFczKGh?	MlvlSG1UVw>?	M4Xy[GlEPTB;MUCg{txO	M{HLdFI{QDR2MEO4
MDA-MB-231	M2\mdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nRW\|ExKM7:TR?=	NFnw[Zo4OiCq	Mn7sSG1UVw>?	M{PqTGlEPTB;MUCg{txO	M2HUeVI{QDR2MEO4
SW756	NHf3O4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVyxNEDPxE1?	MXW3NkBp	NVriUHZITE2VTx?=	NFXuZmFKSzVyPUGwJO69VQ>?	M2XJPFI{QDR2MEO4
SW-837	Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrPNVAh\|ryP	NIP0cIE4OiCq	NH3SfoVFVVOR	MXjJR\|UxRTFyIN88US=>	Ml\qNlM5PDRyM{i=
UMUC-3	NYewWppOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWxNEDPxE1?	NXrIc4VSPzJiaB?=	M2LIWWROW09?	NV;abXhJUUN3ME2xNEDPxE1?	NYT3c2htOjN6NESwN\|g>
LS-174T	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW[xNEDPxE1?	NXq1SlVnPzJiaB?=	M2nyT2ROW09?	NIPoNpJKSzVyPUGwJO69VQ>?	MVeyN\|g1PDB\|OB?=
A549	MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXftNnlyOTBizszN	NHrPZ3Q4OiCq	M1fFbmROW09?	Mme1TWM2OD1zMDFOwG0>	M13ST\|I{QDR2MEO4
SHP-77	NXn4eGZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfIeohIOTBizszN	MVi3NkBp	NFj5cppFVVOR	NETVSldKSzVyPUGwJO69VQ>?	NF64OYczOzh2NECzPC=>
SW480	NIXMdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjKNVAh\|ryP	NFjpPG84OiCq	M3HUPGROW09?	Mm\KTWM2OD1zMDFOwG0>	MUSyN\|g1PDB\|OB?=
DLD-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LGdVExKM7:TR?=	NX:xO5BvPzJiaB?=	NWXwXIcyTE2VTx?=	MofuTWM2OD1zMDFOwG0>	M1nCUFI{QDR2MEO4
HCT-116	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\NNHgyOCEQvF2=	M1;kZlczKGh?	NGPEVVBFVVOR	M2rsWmlEPTB;MUCg{txO	NXLx[GQ4OjN6NESwN\|g>
NCI-H747	NWjufIp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnr4NVAh\|ryP	MV:3NkBp	NFLlbZFFVVOR	Mk\6TWM2OD1zMDFOwG0>	NX64SGNiOjN6NESwN\|g>
T-84	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q1UlExKM7:TR?=	MkH5O\|IhcA>?	MkjsSG1UVw>?	NED6O\|FKSzVyPUGwJO69VQ>?	NFPXS4EzOzh2NECzPC=>
NCI-H460	MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnSO3EyOCEQvF2=	MY[3NkBp	M4HPd2ROW09?	MkDpTWM2OD1zMDFOwG0>	NFX1RlEzOzh2NECzPC=>
Calu-6	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXTNVAh\|ryP	MlnTO\|IhcA>?	M3fZZ2ROW09?	M3LoUWlEPTB;MUCg{txO	M2iyRlI{QDR2MEO4
HCC-2998	NHW3OWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrTWHNEOTBizszN	NV\tVlF5PzJiaB?=	NISwSnhFVVOR	NH7hT4xKSzVyPUGwJO69VQ>?	NX7WO3pDOjN6NESwN\|g>
LS1034	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX:xNEDPxE1?	NF;vVVM4OiCq	MYHEUXNQ	NHzOSZBKSzVyPUGwJO69VQ>?	MWOyN\|g1PDB\|OB?=
CHP-212	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWCxNEDPxE1?	M{DvflczKGh?	NF3pephFVVOR	M3vkfWlEPTB;MUCg{txO	MkjwNlM5PDRyM{i=
SK-N-AS	NInRRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknTNVAh\|ryP	Mn7oO\|IhcA>?	MUfEUXNQ	NIXUcJdKSzVyPUGwJO69VQ>?	NF\rN4MzOzh2NECzPC=>
BFTC-905	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrrc\|AyOCEQvF2=	NYHxRmZOPzJiaB?=	NHK5OW9FVVOR	M{XUfWlEPTB;MUCg{txO	MVeyN\|g1PDB\|OB?=
HuT78	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{T2cFExKM7:TR?=	NInLTVc4OiCq	NXzKTnRrTE2VTx?=	MWLJR\|UxRTV{IH7N	M2j4cFI{QDR2MEO4
RPMI-8226	M{HBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PlelExKM7:TR?=	Mm\CO\|IhcA>?	M1LhfWROW09?	MWjJR\|UxRTJ4MzDuUS=>	NVH1dJlyOjN6NESwN\|g>
BC-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1j2dFExKM7:TR?=	MmDhO\|IhcA>?	NWr0SXI3TE2VTx?=	MY\JR\|UxRTJ5NzDuUS=>	MVKyN\|g1PDB\|OB?=
ACHN	MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX2xNEDPxE1?	NFv4fW84OiCq	M4HRT2ROW09?	MmTHTWM2OD1{OUSgcm0>	NYrQZ2xvOjN6NESwN\|g>
JRT3-T35	M{LFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVSxNEDPxE1?	MUi3NkBp	M3P3c2ROW09?	NUf5OVJvUUN3ME2yPVUhdk1?	MVGyN\|g1PDB\|OB?=
SK-MES-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moj6NVAh\|ryP	NELmeIQ4OiCq	M4DZXWROW09?	NITDboVKSzVyPUOyPUBvVQ>?	MY[yN\|g1PDB\|OB?=
CESS	NIrQfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfiNVAh\|ryP	M3\EbVczKGh?	MVXEUXNQ	MVLJR\|UxRTR7NzDuUS=>	MlrHNlM5PDRyM{i=
H4	NYCwPXdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWxNEDPxE1?	Mn\HO\|IhcA>?	MlnNSG1UVw>?	NFfBfZJKSzVyPU[xPUBvVQ>?	MYCyN\|g1PDB\|OB?=
BC-1	M{\sWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPI[YEyOCEQvF2=	NWC3bFJmPzJiaB?=	MUTEUXNQ	MnjZTWM2OD15MESgcm0>	NV3OTGRlOjN6NESwN\|g>
DB	MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWqzOpRXOTBizszN	MXG3NkBp	MU\EUXNQ	MXLJR\|UxRTh5MzDuUS=>	NF7sSnAzOzh2NECzPC=>
RPMI-6666	NXjFNXR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XNS\|ExKM7:TR?=	NWntPJM1PzJiaB?=	NUGzdHZsTE2VTx?=	Ml75TWM2OD17Mkigcm0>	M3\uVVI{QDR2MEO4
MC/CAR	MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHkOW9TOTBizszN	M3PqVFczKGh?	MV3EUXNQ	Ml3pTWM2OD1zLkCwNkDPxE1?	M1PHWlI{QDR2MEO4
SNU-1	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTEOXkyOCEQvF2=	MlftO\|IhcA>?	M3XnbWROW09?	NYn1Z\|BvUUN3ME2xMlUxOSEQvF2=	NGnPdIwzOzh2NECzPC=>
CEM/C1	MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWWxNEDPxE1?	M3TOb\|czKGh?	Mn7BSG1UVw>?	MVrJR\|UxRTFwN{ezJO69VQ>?	Mn\nNlM5PDRyM{i=
GDM-1	NGTaVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvwWWQyOCEQvF2=	NYGyPZRDPzJiaB?=	M{mwV2ROW09?	NG\HR\|VKSzVyPUGuPVk4KM7:TR?=	NV7BO49pOjN6NESwN\|g>
HT-1080	NF7rSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUflN5drOTBizszN	NEO0cZk4OiCq	NF;Nc4NFVVOR	MoO0TWM2OD1{LkCwOEDPxE1?	MYOyN\|g1PDB\|OB?=
HL-60	M2ra[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LBdFExKM7:TR?=	MlPZO\|IhcA>?	NXvFSZJ{TE2VTx?=	M{DuZmlEPTB;Mj6xO\|gh\|ryP	NWDQR5JrOjN6NESwN\|g>
C3A	NWD3UnRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{mzTVExKM7:TR?=	NWPLXYZ1PzJiaB?=	M32yWmROW09?	NF\yWVdKSzVyPUWuOFE1KM7:TR?=	MmKyNlM5PDRyM{i=
MES-SA	NGH5TWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEThXGkyOCEQvF2=	NV;QbZFnPzJiaB?=	M3zz[GROW09?	MVLJR\|UxRTZwOUi5JO69VQ>?	MlvQNlM5PDRyM{i=
22Rv1	NXPm[HRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\1SYUyOCEQvF2=	NYTJRVRrPzJiaB?=	NGDYemxFVVOR	NIXHeJZKSzVyPUGwJO69VQ>?	NYWzSFA3OjN6NESwN\|g>
647-V	NXXtfZFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYr4PZhVOTBizszN	NUexZ5ltPzJiaB?=	NEj5[WRFVVOR	NWPJV2s1UUN3ME2xNEDPxE1?	MX6yN\|g1PDB\|OB?=
786-O	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnPdJVkOTBizszN	NVPw[I4xPzJiaB?=	NHrybXFFVVOR	MV;JR\|UxRTFyIN88US=>	NY[w[HFUOjN6NESwN\|g>
A172	Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYOxNEDPxE1?	MYK3NkBp	NEfobIVFVVOR	MkntTWM2OD1zMDFOwG0>	MmDUNlM5PDRyM{i=
A204	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnH1NVAh\|ryP	NWrqNFl7PzJiaB?=	M2\5VWROW09?	MVfJR\|UxRTFyIN88US=>	M2\2XVI{QDR2MEO4
A427	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHrVW0yOCEQvF2=	MmXvO\|IhcA>?	M{XXdGROW09?	NXHGTW5NUUN3ME2xNEDPxE1?	MmW1NlM5PDRyM{i=
A431	M2D3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTMOHM1OTBizszN	NX\4WXRQPzJiaB?=	M3fT[WROW09?	NVfNR5VmUUN3ME2xNEDPxE1?	NVntfXBnOjN6NESwN\|g>
A2780	MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnq2NVAh\|ryP	NFjUW2o4OiCq	M{jvWmROW09?	M4Xo[2lEPTB;MUCg{txO	MomxNlM5PDRyM{i=
ARH-77	MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEiySW4yOCEQvF2=	M1jWb\|czKGh?	NEfLdnpFVVOR	NXTCTlJbUUN3ME2xNEDPxE1?	MkmyNlM5PDRyM{i=
Be(2)C	MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\yNVAh\|ryP	MWO3NkBp	NFjhZ\|RFVVOR	NVjjOohDUUN3ME2xNEDPxE1?	NUC5dWNGOjN6NESwN\|g>
BT-20	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jDR\|ExKM7:TR?=	MVm3NkBp	M3r2WGROW09?	NGHXe5pKSzVyPUGwJO69VQ>?	NIrRXWozOzh2NECzPC=>
BxPc3	M1;HVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[0UXREOTBizszN	M{PGRlczKGh?	M1vw[GROW09?	NH3MXmlKSzVyPUGwJO69VQ>?	NYS1R2o{OjN6NESwN\|g>
C-4 I	NE\SbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1KzblExKM7:TR?=	M3vMZlczKGh?	NHzhcoRFVVOR	NWXCWHZoUUN3ME2xNEDPxE1?	Mnu4NlM5PDRyM{i=
C33A	NYLBWJVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXsdGcyOCEQvF2=	MX:3NkBp	NHzUb4xFVVOR	NEXTPVNKSzVyPUGwJO69VQ>?	NHr3WmczOzh2NECzPC=>
CAL-27	NFzxT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo[yNVAh\|ryP	NFKxenA4OiCq	NX;2XFZWTE2VTx?=	MULJR\|UxRTFyIN88US=>	M4nXSVI{QDR2MEO4
CAL-62	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrhVngyOCEQvF2=	NH2ybY44OiCq	NY\JWIRbTE2VTx?=	MVrJR\|UxRTFyIN88US=>	M1jER\|I{QDR2MEO4
Calu-3	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFq0OpMyOCEQvF2=	M3rFUFczKGh?	MmCwSG1UVw>?	M3;GbmlEPTB;MUCg{txO	NYXT[VQxOjN6NESwN\|g>
CaOV3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWO3TXhbOTBizszN	NVrhOmpqPzJiaB?=	MWDEUXNQ	NW[4cXV[UUN3ME2xNEDPxE1?	NH6xRWkzOzh2NECzPC=>
CGTHW1	M1Xxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnBVI8yOCEQvF2=	MWG3NkBp	NYXhTYppTE2VTx?=	MUPJR\|UxRTFyIN88US=>	MkPVNlM5PDRyM{i=
CHL-1	M{\kbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2OzTVExKM7:TR?=	M2HoXVczKGh?	M3e5fWROW09?	MYDJR\|UxRTFyIN88US=>	M4jMdlI{QDR2MEO4
Colo320DM	M2jxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjVd3dQOTBizszN	MnexO\|IhcA>?	NF;mTmpFVVOR	NUD1fJVrUUN3ME2xNEDPxE1?	NV;yXZhQOjN6NESwN\|g>
Colo704	MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[xe5pROTBizszN	MUK3NkBp	NELsVFNFVVOR	MlLRTWM2OD1zMDFOwG0>	NXnSdI1nOjN6NESwN\|g>
COR-L23	M2XhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTXelIxOTBizszN	MVu3NkBp	M4DZcmROW09?	NVPGXHptUUN3ME2xNEDPxE1?	MnnqNlM5PDRyM{i=
CRO-AP2	NGOxOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1v3fFExKM7:TR?=	NYjScFhQPzJiaB?=	MV3EUXNQ	NFLYUHRKSzVyPUGwJO69VQ>?	M1O1[lI{QDR2MEO4
Daudi	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV:xNEDPxE1?	NUTkfIl4PzJiaB?=	NXTE[HF4TE2VTx?=	MV;JR\|UxRTFyIN88US=>	M1;3WlI{QDR2MEO4
DOTC 24510	NGDtT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPtUJVPOTBizszN	MoDMO\|IhcA>?	NIDBR5NFVVOR	MXrJR\|UxRTFyIN88US=>	NVe2NlA6OjN6NESwN\|g>
DU-145	NXfQ[FQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2qxU\|ExKM7:TR?=	NFTOc484OiCq	NFvSemFFVVOR	NX3NWY1EUUN3ME2xNEDPxE1?	M4Ll[FI{QDR2MEO4
EB-3	M4TtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnOWVRuOTBizszN	MX63NkBp	M2ezcWROW09?	MnntTWM2OD1zMDFOwG0>	NWK2bXRpOjN6NESwN\|g>
EFM-19	NHrQenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHuVI94OTBizszN	Mm\ZO\|IhcA>?	NHvXToRFVVOR	M2KwfmlEPTB;MUCg{txO	M4PhbFI{QDR2MEO4
EKVX	M4LyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLMNVAh\|ryP	M3fr[lczKGh?	NVHKOZpZTE2VTx?=	M{jhd2lEPTB;MUCg{txO	NYDpWmlWOjN6NESwN\|g>
FaDu	NVfjeHBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWGxNEDPxE1?	M33PbFczKGh?	NYi5VY9tTE2VTx?=	NEWxVmRKSzVyPUGwJO69VQ>?	MVWyN\|g1PDB\|OB?=
G401	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml[3NVAh\|ryP	MnfhO\|IhcA>?	MUfEUXNQ	Mlf1TWM2OD1zMDFOwG0>	MmHhNlM5PDRyM{i=
HCC-70	M2nkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknENVAh\|ryP	M37EVVczKGh?	NIjLb4xFVVOR	NW\TdpdIUUN3ME2xNEDPxE1?	MnvlNlM5PDRyM{i=
HCC-1954	NWmxXopbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVGxNEDPxE1?	MlXDO\|IhcA>?	NFywXlRFVVOR	MXnJR\|UxRTFyIN88US=>	NFfXeZUzOzh2NECzPC=>
Hela	MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXQZo1sOTBizszN	MkPtO\|IhcA>?	NEK4cZJFVVOR	NWjqfFR7UUN3ME2xNEDPxE1?	MkTaNlM5PDRyM{i=
Hep3B	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnKeZQyOCEQvF2=	NETBcIE4OiCq	NXj1c5pzTE2VTx?=	NWnGcY4yUUN3ME2xNEDPxE1?	MYOyN\|g1PDB\|OB?=
HMCB	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVr1SYVqOTBizszN	NVHDeJA6PzJiaB?=	NYfsVJg2TE2VTx?=	MXjJR\|UxRTFyIN88US=>	NUjNc5EyOjN6NESwN\|g>
HN5	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TFUFExKM7:TR?=	MoPFO\|IhcA>?	MlnBSG1UVw>?	M17BXWlEPTB;MUCg{txO	NVPURoduOjN6NESwN\|g>
HOS	Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELNeXIyOCEQvF2=	NY\vVnZjPzJiaB?=	M1G5RWROW09?	M13NOGlEPTB;MUCg{txO	NFrXT3ozOzh2NECzPC=>
HPAF-II	NVvnPXQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[yRYJlOTBizszN	NVHzOVlrPzJiaB?=	MmnjSG1UVw>?	NEPlSZJKSzVyPUGwJO69VQ>?	Mn6yNlM5PDRyM{i=
Hs746.T	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\SRlExKM7:TR?=	MlnuO\|IhcA>?	M1zjb2ROW09?	MmD0TWM2OD1zMDFOwG0>	NEnqRoYzOzh2NECzPC=>
HT	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7mNVAh\|ryP	MXK3NkBp	MV3EUXNQ	NHzQb\|ZKSzVyPUGwJO69VQ>?	NXKyd41UOjN6NESwN\|g>
HT-3	NX;NfWlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PJSVExKM7:TR?=	M3nzW\|czKGh?	NYq0fJl[TE2VTx?=	M{XRdWlEPTB;MUCg{txO	NFq4O\|UzOzh2NECzPC=>
HuNS-1	NUC0WoJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DzV\|ExKM7:TR?=	NWPRN\|IxPzJiaB?=	MnXHSG1UVw>?	NGrG[GRKSzVyPUGwJO69VQ>?	MlLQNlM5PDRyM{i=
IGROV1	MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\ENlIyOCEQvF2=	NVHWNYpFPzJiaB?=	Mle3SG1UVw>?	MnvnTWM2OD1zMDFOwG0>	M3jYe\|I{QDR2MEO4
J82	MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fqflExKM7:TR?=	MXy3NkBp	NY\hU\|ZHTE2VTx?=	MlLRTWM2OD1zMDFOwG0>	M2K4WVI{QDR2MEO4
JM1	NWjQT5FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTuNVAh\|ryP	MorTO\|IhcA>?	MYTEUXNQ	NWr0ZpZOUUN3ME2xNEDPxE1?	NVTJT5dCOjN6NESwN\|g>
Kato III	M37LcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7wNVAh\|ryP	NXW2e403PzJiaB?=	MWLEUXNQ	MVTJR\|UxRTFyIN88US=>	NV7zSZR[OjN6NESwN\|g>
KHOS-240S	M3zOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEH4WZkyOCEQvF2=	NGK2eHM4OiCq	Mn3PSG1UVw>?	NWi2UYRQUUN3ME2xNEDPxE1?	NY\YSnRROjN6NESwN\|g>
KM-12	NHrRdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3UNVAh\|ryP	MoKyO\|IhcA>?	NGr6cXFFVVOR	NULyUHZSUUN3ME2xNEDPxE1?	MYKyN\|g1PDB\|OB?=
KPL-1	MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\B[mgyOCEQvF2=	MXi3NkBp	NYjGV\|NsTE2VTx?=	NVfteoRjUUN3ME2xNEDPxE1?	M1fnNFI{QDR2MEO4
KYSE-30	MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\KN\|ExKM7:TR?=	MmK1O\|IhcA>?	NYLNO2l2TE2VTx?=	MoDhTWM2OD1zMDFOwG0>	NV75R5hDOjN6NESwN\|g>
LNCaP	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVv6VpFEOTBizszN	MWq3NkBp	NGDuZ2dFVVOR	M1TPcGlEPTB;MUCg{txO	MUKyN\|g1PDB\|OB?=
MCF-7	NUn1[I5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TyZ\|ExKM7:TR?=	M{LOflczKGh?	M3XKPGROW09?	NYPRO5pYUUN3ME2xNEDPxE1?	MmfpNlM5PDRyM{i=
MC-IXC	Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXviV4dJOTBizszN	NE\PU\|k4OiCq	MmTxSG1UVw>?	NGTiR\|lKSzVyPUGwJO69VQ>?	MWSyN\|g1PDB\|OB?=
MDA-MB-175 VII	MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYixNEDPxE1?	MXi3NkBp	NV74PZIyTE2VTx?=	NILSZ2xKSzVyPUGwJO69VQ>?	Ml[3NlM5PDRyM{i=
MDA-MB-468	M2T3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEG0TW0yOCEQvF2=	MY[3NkBp	NIG4TFNFVVOR	NYjCOpVOUUN3ME2xNEDPxE1?	M2XzbVI{QDR2MEO4
MiaPaCa	NXLNbpVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIH0SmcyOCEQvF2=	MWi3NkBp	NHvyVlNFVVOR	Mn7vTWM2OD1zMDFOwG0>	NUHjToY{OjN6NESwN\|g>
Molt-4	NXH6RnAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LYOlExKM7:TR?=	NIrVdlc4OiCq	MUPEUXNQ	M4fid2lEPTB;MUCg{txO	MlnFNlM5PDRyM{i=
NCI-ADR/RES	Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mor5NVAh\|ryP	Mkm0O\|IhcA>?	MX\EUXNQ	M2jmbGlEPTB;MUCg{txO	MlK5NlM5PDRyM{i=
NCI-H69	NVTkWJRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVGxNEDPxE1?	MYe3NkBp	NITQOnlFVVOR	M{LT[2lEPTB;MUCg{txO	NULnSYpDOjN6NESwN\|g>
NCI-H82	MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3W4bFExKM7:TR?=	MWG3NkBp	NF3VNJFFVVOR	NFL6RXpKSzVyPUGwJO69VQ>?	M4P0[VI{QDR2MEO4
NCI-N87	M3;oWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1ztflExKM7:TR?=	MmPQO\|IhcA>?	MleySG1UVw>?	MVvJR\|UxRTFyIN88US=>	MYGyN\|g1PDB\|OB?=
NCI-H146	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfaZnQyOCEQvF2=	MVG3NkBp	NEPHUItFVVOR	NH7LOGdKSzVyPUGwJO69VQ>?	MoK1NlM5PDRyM{i=
NCI-H157	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7zN4gyOCEQvF2=	M13ac\|czKGh?	MWTEUXNQ	MnL3TWM2OD1zMDFOwG0>	NXTDfnA5OjN6NESwN\|g>
NCI-H187	NVzHXXZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYKxNEDPxE1?	MnPQO\|IhcA>?	M3PsUWROW09?	Ml76TWM2OD1zMDFOwG0>	Ml\HNlM5PDRyM{i=
NCI-H209	NEnLNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYWxNEDPxE1?	NIjtcFE4OiCq	NV;DfnZNTE2VTx?=	MnTOTWM2OD1zMDFOwG0>	NXzKUlJEOjN6NESwN\|g>
NCI-H226	NXfpd4NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHmXoVbOTBizszN	MkPsO\|IhcA>?	MXHEUXNQ	NF\DeWRKSzVyPUGwJO69VQ>?	MlPBNlM5PDRyM{i=
NCI-H292	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7zNVAh\|ryP	MWS3NkBp	MkHzSG1UVw>?	MUTJR\|UxRTFyIN88US=>	Mln5NlM5PDRyM{i=
NCI-H322	M165d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnvZlBrOTBizszN	M1PWOlczKGh?	M1nSSGROW09?	M1vj[GlEPTB;MUCg{txO	MXKyN\|g1PDB\|OB?=
NCI-H358	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTEXXBwOTBizszN	MU[3NkBp	Mn;rSG1UVw>?	MYHJR\|UxRTFyIN88US=>	MoDTNlM5PDRyM{i=
NCI-H520	NIHwWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XPUVExKM7:TR?=	NIPxcJk4OiCq	MX7EUXNQ	NHjNWIRKSzVyPUGwJO69VQ>?	NFjqWIczOzh2NECzPC=>
NCI-H526	NF20[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M16wNlExKM7:TR?=	NXmwZWpPPzJiaB?=	M1vVe2ROW09?	M1PDPWlEPTB;MUCg{txO	M2\XV\|I{QDR2MEO4
NCI-H630	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vwTlExKM7:TR?=	M3fncFczKGh?	NUO2W\|NJTE2VTx?=	NWHxbVdkUUN3ME2xNEDPxE1?	M{TQWlI{QDR2MEO4
NCI-H661	MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY[wSYVzOTBizszN	MXK3NkBp	MnrwSG1UVw>?	NV7B[GR7UUN3ME2xNEDPxE1?	MXeyN\|g1PDB\|OB?=
NCI-H716	NHn2dnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjjcIJIOTBizszN	M3zYNVczKGh?	NHj1NYpFVVOR	NV;hU4lrUUN3ME2xNEDPxE1?	NHrveGkzOzh2NECzPC=>
NCI-H1563	M4XQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWexNEDPxE1?	M1n1PVczKGh?	NHXPfmVFVVOR	M4fQZmlEPTB;MUCg{txO	MoDLNlM5PDRyM{i=
NCI-H1792	M4Xzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVu5OVdmOTBizszN	MUS3NkBp	NYrMfnROTE2VTx?=	NG[y[GlKSzVyPUGwJO69VQ>?	M4HrS\|I{QDR2MEO4
NCI-H2030	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYKybHJoOTBizszN	MYK3NkBp	NFXFcW9FVVOR	MVrJR\|UxRTFyIN88US=>	NH\zb5czOzh2NECzPC=>
NCI-H2052	M{PuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY[xNEDPxE1?	M1LLclczKGh?	MkLiSG1UVw>?	M4KwTGlEPTB;MUCg{txO	Mn3INlM5PDRyM{i=
NCI-H2122	NU\ieWFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nsOVExKM7:TR?=	MmOyO\|IhcA>?	NV3sNGxOTE2VTx?=	NE\uT4ZKSzVyPUGwJO69VQ>?	NVTZUoRyOjN6NESwN\|g>
NCI-H2228	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PlclExKM7:TR?=	MWe3NkBp	NHf0PIhFVVOR	NFvidpFKSzVyPUGwJO69VQ>?	NX2xcYlpOjN6NESwN\|g>
OE-19	M1zNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUSxNEDPxE1?	NVL3cm5xPzJiaB?=	MoPKSG1UVw>?	NVzsNXFjUUN3ME2xNEDPxE1?	NGTucGUzOzh2NECzPC=>
OE-21	NFm4UVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\yTXl[OTBizszN	MomzO\|IhcA>?	M2XtOGROW09?	NFzsRXpKSzVyPUGwJO69VQ>?	MXyyN\|g1PDB\|OB?=
OE-33	NHm4cG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXBNVAh\|ryP	NInXSlI4OiCq	M2\OOWROW09?	MkLJTWM2OD1zMDFOwG0>	MkT4NlM5PDRyM{i=
OVCAR-3	NU\mNXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXj[YpnOTBizszN	MoLTO\|IhcA>?	NYLmd\|ZxTE2VTx?=	Ml7yTWM2OD1zMDFOwG0>	NF;yTZQzOzh2NECzPC=>
OVCAR-4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInLT5UyOCEQvF2=	MnLqO\|IhcA>?	M1G4RmROW09?	Mnm4TWM2OD1zMDFOwG0>	MYCyN\|g1PDB\|OB?=
OVCAR-5	M1r0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEW4TFIyOCEQvF2=	MUO3NkBp	NXrycow3TE2VTx?=	NHXJUpJKSzVyPUGwJO69VQ>?	NY\1Xo1MOjN6NESwN\|g>
P3HR-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnx[5dyOTBizszN	NH7VeHk4OiCq	MVnEUXNQ	MkK4TWM2OD1zMDFOwG0>	NUnXSopuOjN6NESwN\|g>
PC-3	M{nLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWSxNEDPxE1?	NUH3UW9VPzJiaB?=	M4DEN2ROW09?	Ml3PTWM2OD1zMDFOwG0>	MX[yN\|g1PDB\|OB?=
Raji	M3vGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\BT\|ExKM7:TR?=	MV63NkBp	MojGSG1UVw>?	MmfSTWM2OD1zMDFOwG0>	MmfQNlM5PDRyM{i=
RD	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrkTVN4OTBizszN	MWi3NkBp	MVfEUXNQ	M3\zVGlEPTB;MUCg{txO	NEHhTWIzOzh2NECzPC=>
RD-ES	NFHrS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LJTFExKM7:TR?=	M{nzb\|czKGh?	MU\EUXNQ	NFj1TVRKSzVyPUGwJO69VQ>?	M2ThUVI{QDR2MEO4
RL	M{Llemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWKxNEDPxE1?	MlvqO\|IhcA>?	NE\BXFlFVVOR	NEXYfnpKSzVyPUGwJO69VQ>?	MkS2NlM5PDRyM{i=
SaOS2	NFezUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUW1VZhPOTBizszN	NWTBcIlDPzJiaB?=	MnvFSG1UVw>?	M{PLSWlEPTB;MUCg{txO	MmfyNlM5PDRyM{i=
SCC-9	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTjT3AyOCEQvF2=	M3zRRlczKGh?	NH7u[YdFVVOR	NF3T[mRKSzVyPUGwJO69VQ>?	MXGyN\|g1PDB\|OB?=
SCC-12	NIfqW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HyclExKM7:TR?=	MXe3NkBp	MlvTSG1UVw>?	MoHpTWM2OD1zMDFOwG0>	M1;Vc\|I{QDR2MEO4
SCC-13	NET3cVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDRfXEyOCEQvF2=	NX;MRnNnPzJiaB?=	M3HCeWROW09?	MYPJR\|UxRTFyIN88US=>	NFjyc3QzOzh2NECzPC=>
SCC-15	NE\BOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PM[VExKM7:TR?=	NV\QU2JQPzJiaB?=	M2XrbmROW09?	MV;JR\|UxRTFyIN88US=>	MUKyN\|g1PDB\|OB?=
SCC-25	NEfNc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LmOVExKM7:TR?=	NXzBTHNNPzJiaB?=	MVvEUXNQ	NVHjNWdHUUN3ME2xNEDPxE1?	NVfNVm8xOjN6NESwN\|g>
SCLC-3	NHjsdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nOUFExKM7:TR?=	MWe3NkBp	M4fwZmROW09?	MYTJR\|UxRTFyIN88US=>	NV7OR\|Y2OjN6NESwN\|g>
SF-268	MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3pNnkyOCEQvF2=	MVu3NkBp	NEHWS\|FFVVOR	NGC5NIVKSzVyPUGwJO69VQ>?	NFf1XnEzOzh2NECzPC=>
SF-295	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrkfogyOCEQvF2=	NF7zXok4OiCq	NWKyfGhrTE2VTx?=	NEiwXmdKSzVyPUGwJO69VQ>?	NEHJbVMzOzh2NECzPC=>
SJRH30	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3za[lExKM7:TR?=	NYLKVZFvPzJiaB?=	MXrEUXNQ	NYriVod6UUN3ME2xNEDPxE1?	MVKyN\|g1PDB\|OB?=
SK-BR-3	NYG5PZJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1uzW\|ExKM7:TR?=	NUfMVY1lPzJiaB?=	MmDrSG1UVw>?	M2m2ZWlEPTB;MUCg{txO	NHj0WZczOzh2NECzPC=>
SK-LMS-1	M3Xve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3wNVAh\|ryP	MWC3NkBp	MXHEUXNQ	NV;iZ2k4UUN3ME2xNEDPxE1?	M{ns[lI{QDR2MEO4
SK-N-DZ	M1TT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOxNEDPxE1?	NIjEcnI4OiCq	NGXXSpNFVVOR	NXXyZ4I5UUN3ME2xNEDPxE1?	NF:xbmszOzh2NECzPC=>
SK-N-F1	NUjlXnlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\rW\|cyOCEQvF2=	M1nYbFczKGh?	NV3nOGdYTE2VTx?=	NIqyNmpKSzVyPUGwJO69VQ>?	NHK0c3gzOzh2NECzPC=>
SKOV-3	MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXwfJQyOCEQvF2=	M2freVczKGh?	MnfLSG1UVw>?	NWDi[m4xUUN3ME2xNEDPxE1?	Mki5NlM5PDRyM{i=
SK-UT-1	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnrcXoyOCEQvF2=	M3njWFczKGh?	NEHtd\|RFVVOR	MnvVTWM2OD1zMDFOwG0>	MUCyN\|g1PDB\|OB?=
SN12C	MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nhVlExKM7:TR?=	NH[zSGo4OiCq	NFHXUGNFVVOR	MkLxTWM2OD1zMDFOwG0>	NX7xcZduOjN6NESwN\|g>
SNB-19	M1i2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3i0O\|ExKM7:TR?=	MlnvO\|IhcA>?	MUXEUXNQ	MmPUTWM2OD1zMDFOwG0>	NXnHN4kyOjN6NESwN\|g>
SNU-5	NXryWFdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX6xNEDPxE1?	NIjsU\|g4OiCq	NXu1NGszTE2VTx?=	NYjCS5FvUUN3ME2xNEDPxE1?	NFmybGczOzh2NECzPC=>
SNU-16	M4ToPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jmSlExKM7:TR?=	Ml7YO\|IhcA>?	MV3EUXNQ	NUO2VZFtUUN3ME2xNEDPxE1?	M3uzSVI{QDR2MEO4
SNU-398	NVjK[HE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDtNVAh\|ryP	MVi3NkBp	NHnpe4FFVVOR	NVTOS5RzUUN3ME2xNEDPxE1?	NUDz[VdKOjN6NESwN\|g>
SNU-449	M{DlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjVZ2tZOTBizszN	MUC3NkBp	M3ezc2ROW09?	M2nVVGlEPTB;MUCg{txO	MUmyN\|g1PDB\|OB?=
SR	NYLmSYE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mle0NVAh\|ryP	MUO3NkBp	NFK1d4tFVVOR	NX:2T2hsUUN3ME2xNEDPxE1?	NYnpflZMOjN6NESwN\|g>
ST486	NH70XlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWCxNEDPxE1?	M1f0VFczKGh?	NEfZTpBFVVOR	NEPaOXRKSzVyPUGwJO69VQ>?	M3:we\|I{QDR2MEO4
SW579	M{nCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;iN\|ExKM7:TR?=	NGG2PVc4OiCq	MkHjSG1UVw>?	MV7JR\|UxRTFyIN88US=>	M{PQV\|I{QDR2MEO4
SW684	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHjVmcyOCEQvF2=	MofDO\|IhcA>?	NV[5N4lUTE2VTx?=	NHniVmVKSzVyPUGwJO69VQ>?	NGP2d\|EzOzh2NECzPC=>
SW-780	NG\BU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLGNVAh\|ryP	NYXBZ215PzJiaB?=	NETFSo1FVVOR	NF\DV2xKSzVyPUGwJO69VQ>?	MkLZNlM5PDRyM{i=
SW900	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7SNVAh\|ryP	NY\FR5BXPzJiaB?=	M1jGZWROW09?	NFrldnNKSzVyPUGwJO69VQ>?	Ml64NlM5PDRyM{i=
SW1088	NGrnSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX[xNEDPxE1?	Mn;5O\|IhcA>?	MlzXSG1UVw>?	NFe1ZmFKSzVyPUGwJO69VQ>?	NIHnRYQzOzh2NECzPC=>
SW1463	M2jBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmj5NVAh\|ryP	MXS3NkBp	NXnCUlFiTE2VTx?=	M1K2OGlEPTB;MUCg{txO	MUWyN\|g1PDB\|OB?=
SW1990	NYr5UWZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoqwNVAh\|ryP	NIHoUII4OiCq	NYSwUXN[TE2VTx?=	M3XpN2lEPTB;MUCg{txO	NVnkcos5OjN6NESwN\|g>
T47D	NFvGVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWGxNEDPxE1?	NVHkfo9LPzJiaB?=	NF35dYdFVVOR	MmPITWM2OD1zMDFOwG0>	NUXlUHFiOjN6NESwN\|g>
TE381.T	NUPYO4htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnOTnIyOCEQvF2=	MYC3NkBp	M2rRTWROW09?	M{jVXGlEPTB;MUCg{txO	M2fLNFI{QDR2MEO4
TK-10	NFvVU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWexNEDPxE1?	NGqzTmg4OiCq	Mlm5SG1UVw>?	NHfTfYRKSzVyPUGwJO69VQ>?	NUHW[4JVOjN6NESwN\|g>
U2OS	M4HYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7VRo1uOTBizszN	NEfScXc4OiCq	M4DkRmROW09?	NIG5S21KSzVyPUGwJO69VQ>?	NWXTVW1ZOjN6NESwN\|g>
U251	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVuxNEDPxE1?	M{XZRVczKGh?	NUG2VVBSTE2VTx?=	NFXP[pdKSzVyPUGwJO69VQ>?	M3G4eFI{QDR2MEO4
UACC-812	M2HFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWmxNEDPxE1?	NV3Dd\|NMPzJiaB?=	MVrEUXNQ	NH;iT\|dKSzVyPUGwJO69VQ>?	NIDrb4gzOzh2NECzPC=>
YAPC	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfVTpAyOCEQvF2=	MmfJO\|IhcA>?	NEKzcmdFVVOR	MnrLTWM2OD1zMDFOwG0>	MlzCNlM5PDRyM{i=
ZR-75-1	M3jaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TKVFExKM7:TR?=	MV:3NkBp	M2jwN2ROW09?	M1OzV2lEPTB;MUCg{txO	NWHDU5ZPOjN6NESwN\|g>
A375	NXzhdFYyTnWwY4Tpc44h[XO\|YYm=	M{HYfVEvOiEQvF2=	MVm0JIg>	MYPEUXNQ	NUPOWFN3UW6qaXLpeIlwdiCxZjDwbI9{eGixconsZZRqd25ib3[gUWVMNCCHUlusJIFv\CCVNmC=	NGLRXYwzOjN6OUS3NS=>
YUSIT1	NH\3ZmVHfW6ldHnvckBie3OjeR?=			MmTMSG1UVw>?	MVfy[YR2[2WmIIPlcpNqfGm4aYT5JJdqfGhiSVO1NEA,KDBwNTFOwG0>	MXWyNlM5QTR5MR?=
MeWo	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MVnEUXNQ	MYXJR\|UxKD1iOUi3JI5O	M4nhb\|I3ODF6NUK0
WiDr	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M2nPOGROW09?	NFHaeGJKSzVyIE2gO\|Yhdk1?	NYnnUWJpOjZyMUi1NlQ>
Colo-205	MkDKSpVv[3Srb36gZZN{[Xl?	MY[xJO69VQ>?	MVm0JIQ>	M4Ps[2ROW09?	NX\Pe2VmUW6mdXPl[EBiKGirZ3jsfUBkd22yYYLhZoxmKGOxbYDhZ5Rqd25icHjlco91gXCn	MUmyOVM5OTF3Mh?=
RBW-1	NETCTZVHfW6ldHnvckBie3OjeR?=	MonmNUDPxE1?		NXf5[lJQTE2VTx?=	M{naT25wKHKnZIXjeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	M4f3SVI1QDh3Nkmw
RBO-1	M1Szd2Z2dmO2aX;uJIF{e2G7	NYjQUndQOSEQvF2=		NFrCfXFFVVOR	NWD4e2NbUW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	NYG5d5lpOjR6OEW2PVA>
RBO-2	NYrjbGlMTnWwY4Tpc44h[XO\|YYm=	MYmxJO69VQ>?		NHfh[phFVVOR	M{LubWlvcGmkaYTpc44hd2ZiIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v	NHH0U3kzPDh6NU[5NC=>
RBOW	NVOzZmFuTnWwY4Tpc44h[XO\|YYm=	M13FU\|Eh\|ryP		MUXEUXNQ	NIrMNohKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	NH3BOIgzPDh6NU[5NC=>
M257	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUmxNFAhdk1?	NV7ZS2N1PzJiaB?=		NGXzcpZFd2W\|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	NXHEfIk1OjN\|MUe0OFY>
LCP	NGnZTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXGxdYczOTByIH7N	M1PKb\|czKGh?		NWGzSIZsUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	M2PaSFI{OzF5NES2
WM266	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUexNFAhdk1?	NV2xU5VNPzJiaB?=		NG\pW2tKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiV12yOlYh[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNWQhdXW2YX70ZZRqd25?	NFzKUXYzOzNzN{S0Oi=>
M257	NVvoTY43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXzNVAxKG6P	NYfTfWVWPzJiaB?=		M1fYS2Rw\XNibn;0JIlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDNNlU4KGOnbHygbIFz[m:3cnnu[{B4cWymIIT5dIUhSlKDRh?=	MWWyN\|MyPzR2Nh?=
LCP	MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{C0OFExOCCwTR?=	NGHvdYw4OiCq		M3HqRWlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDMR3Ah[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNHIhdXW2YX70ZZRqd25?	NIjo[GIzOzNzN{S0Oi=>
WM266	NVT6TYp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPyNVAxKG6P	M2DvVFczKGh?		NXnRT3hWUW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJHdOOjZ4IHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCGIH31eIFvfGG2aX;u	M3HlOVI{OzF5NES2

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

体内研究

Dabrafenib（口服）抑制B-RafV600E突变的黑色素瘤（A375P）的生长，在免疫受损小鼠中皮下注射结肠癌（Colo205），Dabrafenib（口服）同样能抑制肿瘤生长。 ^[1]

参考文献

溶解度 (25°C)

体外	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+45% PEG 300+2% Tween 80+ddH2O	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dabrafenib (GSK2118436) SDF

分子量	519.56
化学式	C₂₃H₂₀F₃N₅O₂S₂
CAS号	1195765-45-7
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2
NCT03668431	Recruiting	Drug: Dabrafenib\|Drug: Trametinib\|Drug: PDR001	Metastatic Colorectal Cancer	Massachusetts General Hospital\|Novartis\|Stand Up To Cancer	October 15 2018	Phase 2
NCT03553329	Completed	Drug: dabrafenib	Unresecable Stage IIIc or IV Melanoma	Poitiers University Hospital	June 2 2018	--
NCT03593993	Recruiting	Procedure: Surgical Cohort	Glioma\|BRAF V600E\|Pleomorphic Xantho-Astrocytoma\|Glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Musella Foundation	May 19 2018	--
NCT03340506	Recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma\|Non Small Cell Lung Cancer\|Solid Tumor\|Rare Cancers\|High Grade Glioma	Novartis Pharmaceuticals\|Novartis	December 28 2017	Phase 4

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

泛Raf抑制剂

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA批准的Raf抑制剂

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
最新的Raf抑制剂

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

研究领域

产品类型

Dabrafenib (GSK2118436)

客户使用Selleck生产的Dabrafenib (GSK2118436)发表文献135篇：

产品安全说明书

Raf抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dabrafenib (GSK2118436) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

相关Raf产品